Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK/PD of Oral Ecnoglutide (XW004) in Healthy and Obese Adults
NCT05184322Phase 1Completed
- Sponsor
- Sciwind Biosciences
- Start
- Apr 2022
- Primary completion
- Jul 2024
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ecnoglutide in obesity and type 2 diabetes mellitus (T2DM) (6 cohorts), sponsored by Sciwind Biosciences. Primary endpoint: Treatment Emergent Adverse Events and Serious Adverse Events up to 98 days. Started Apr 2022; status: completed.
02
Drugs
ecnoglutide
03
Conditions
obesitytype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT05184322.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05184322.